Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
-8-K As previously disclosed, on December 11, 2022, Horizon Therapeutics plc (“Horizon”), Amgen Inc. (“Amgen”) and Pillartree ...
-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses --Horizon Therap...
-- Additional data presented at ATA 2023 include a subgroup analysis from the TEPEZZA Phase 4 clinical trial and insights on th...
Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Rα antibody that re-regulates adaptive im...
-- Alopecia areata is the second autoimmune indication being evaluated for bempikibart --
